Childhood Kidney Diseases

  • 제18권1호
  • /
  • Pages.24-28
  • /
  • 2014
  • /
  • 2384-0242(pISSN)
  • /
  • 2384-0250(eISSN)
대한소아신장학회 (Korean Society of Pediatric Nephrology)
권호 표지
DOI QR코드

DOI QR Code

단백뇨를 동반한 IgA 신병증 및 HSP 신염을 가진 소아에서 메틸프레드니솔론 충격요법과 경구 스테로이드 요법의 비교

Comparison of the Therapeutic Efficacy of Methylprednisolone Pulse Therapy and Oral Steroid Therapy in Children with IgA Nephropathy and HSP Nephritis Combined with Proteinuria

  • 안지영 (경북대학교 의학전문대학원 소아과학교실) ;
  • 문정은 (경북대학교 의학전문대학원 소아과학교실) ;
  • 황영주 (경북대학교 의학전문대학원 소아과학교실) ;
  • 최봉석 (경북대학교 의학전문대학원 소아과학교실) ;
  • 고철우 (경북대학교 의학전문대학원 소아과학교실) ;
  • 조민현 (경북대학교 의학전문대학원 소아과학교실)
  • Ahn, Ji Young (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Moon, Jung Eun (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Hwang, Young Ju (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Choi, Bong Seok (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Ko, Cheol Woo (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Cho, Min Hyun (Department of Pediatrics, Kyungpook National University School of Medicine)
  • 투고 : 2014.02.20
  • 심사 : 2014.04.03
  • 발행 : 2014.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 본 연구는 단백뇨를 동반한 IgA 신병증과 HSP신염을 가진 소아환자에서 메틸프레드니솔론 충격요법의 단백뇨 감소효과를 확인하고자 시행되었다. 방법: 경북대학교병원 소아청소년과에서 신장조직검사를 통해 IgA 신병증 및 HSP 신염으로 진단받은 21명의 환자의 임상기록을 후향적으로 조사하였다. 총 21명 중 15명 은 IgA 신병증으로, 6명은 HSP 신염으로 진단되었으며 이들 모두 진단 당시 혹은 경과 관찰 중 경도 이상의 단백뇨를 동반하였다. 이들 중 7명(IgA 신병증 5명, HSP 신염 2명; Group 1)에 대해서는 2개월 간격으로 모두 3회의 메틸프레드니솔론 충격요법이 시행되었으며 나머지 14명(IgA 신병 증 10명, HSP 신염 4명; Group 2)에 대해서는 경구 스테로이드요법이 시행되었다. 결과: Group 1의 평균 진단 당시 연령과 조직검사 당시 연령은 Group 2에 비해 어린 경향을 보였으나 통계적인 차이는 없었다. 내원 당시 두 군의 모든 환자는 혈뇨를 동반하였으며 Group 1의 5명(71.4%)과 Group 2의 14명 (100%)은 단백뇨를 동반하였다. 수축기 평균 혈압은 두 군간에 유의한 차이가 없었으며 안지오텐신 전환효소 억제제는 두 군의 모든 환자에서 사용되었다. 추적관찰 기간 동안 단백뇨가 소실된 환자는 Group 1이 7명(100%), Group 2이 10명(71.4%)이었고 일회 소변 단백/크레아티닌의 비가 각각 0.12 (0.06-0.26) mg/mg, 0.30 (0.09-0.79) mg/mg으로 Group 1의 단백뇨가 통계적으로 유의하게 적었다. 결론: 단백뇨를 동반한 IgA 신병증 및 HSP 신염 환자에서 경구 스테로이드요법에 비해 메틸프레드니솔론 충격요법의 단백뇨 감소 효과가 더 뛰어남을 알 수 있었다. 다수의 환자를 대상으로 장기적인 예후에 대한 효과를 알아보기 위한 전향적인 추가 연구가 필요하다고 사료된다.

Purpose: The purpose of this study was to assess the therapeutic efficacy of methylprednisolone pulse therapy in children with IgA nephropathy and Henoch- Sch$\ddot{o}$nlein Purpura (HSP) nephritis combined with proteinuria. Methods: We retrospectively reviewed the clinical records of 21 patients who were diagnosed with IgA nephropathy and HSP nephritis based on percutaneous renal biopsy. Of the 21 patients, 15 were diagnosed with IgA nephropathy and 6 were diagnosed with HSP nephritis. They had mild to severe proteinuria at the time of diagnosis or during follow-up. Group 1 (n=7) received methylprednisolone pulse therapy three times every couple of months, and Group 2 (n=14) received oral steroid therapy. The follow-up periods for Group 1 and 2 were 14.0 (9-54) months and 26.5 (14-34) months, respectively. There was no significant difference in the follow-up duration between the two groups. Results: The average age at diagnosis and biopsy was lower in Group 1 compared to Group 2, but it was not significantly different. At admission, all patients in both groups had hematuria and 5 patients (71.4%) of Group 1 and 14 patients (100 %) of Group 2 had proteinuria. Before treatment, there was no significant difference of spot urine protein/creatinine ratio between the two groups. During followup, 7 patients of Group 1 (100%) and 10 patients of Group 2 (71.4%) showed complete improvement of proteinuria and the spot urine protein/creatinine ratio in Group 1 was significantly lower than Group 2. Conclusion: In patients with IgA nephropathy and HSP nephritis with proteinuria, methylprednisolone pulse therapy was more effective than oral steroid therapy in the reduction of proteinuria. To investigate the effects on long-term prognosis, large-scale prospective studies are needed.

키워드

참고문헌

  1. Lv J, Zhang H, Zhou Y, Li G, Zou W, Wang H. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: A long-term follow up of 204 cases in China. Nephrology (Carlton) 2008;13: 242-6. https://doi.org/10.1111/j.1440-1797.2007.00898.x
  2. Ahn HS. Pediatrics (Korean) 2012;10th edition:885-8.
  3. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S. Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 1996;72:237-42. https://doi.org/10.1159/000188848
  4. Ronkainen J, Autio-Harmainen H, Nuutinen M. Cyclosporin A for the treatment of severe Henoch-Scho¨ nlein glomerulonephritis. J Pediatr Nephrol 2003;18:1138-42. https://doi.org/10.1007/s00467-003-1245-7
  5. Ronkainen J, Ala-Houhala M, Antikainen M. Cyclosporine A (CyA) versus MP pulses (MP) in the treatment of severe Henoch-Schonlein Nephritis (HSN). Pediatr Nephrol 2006;21: 1531.
  6. Waldo FB, Wyatt RJ, Kelly DR, Herrera GA, Benfield MR, Kohaut EC. Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone. Pediatr Nephrol 1993;7:529-32. https://doi.org/10.1007/BF00852535
  7. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomized controlled trial. Lancet 1999;353:883-7. https://doi.org/10.1016/S0140-6736(98)03563-6
  8. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: longterm results of a randomized, controlled trial. J Am Soc Nephrol 2004;15:157-63. https://doi.org/10.1097/01.ASN.0000103869.08096.4F
  9. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987;64:709-27.
  10. Julian BA, Waldo FB, Rifai A, Mestecky J. IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? Am J Med 1988;84:129-32.
  11. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347:738-48. https://doi.org/10.1056/NEJMra020109
  12. Davin JC, Ten Berge IJ, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis? Kidney Int 2001;59:823-34. https://doi.org/10.1046/j.1523-1755.2001.059003823.x
  13. D'Amico G. Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis 2000;36:227-37. https://doi.org/10.1053/ajkd.2000.8966
  14. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004;24:179-96. https://doi.org/10.1016/j.semnephrol.2004.01.001
  15. Wakai K, Kawamura T, Endoh M, Kojima M, Tomino Y, Tamakoshi A, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant 2006;21:2800-8. https://doi.org/10.1093/ndt/gfl342
  16. Wakai K, Kawamura T, Matsuo S, Hotta N, Ohno Y. Risk factors for IgA nephropathy: a case-control study in Japan. Am J Kidney Dis 1999;33:738-45. https://doi.org/10.1016/S0272-6386(99)70228-3
  17. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997;8:199-207.
  18. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011;22:752-61. https://doi.org/10.1681/ASN.2010040355
  19. Davin JC, Weening JJ. Henoch-Schönlein purpura nephritis: an update. Eur J Pediatr 2001;160:689-95. https://doi.org/10.1007/s004310100841
  20. Goldstein AR, White RHR, Akuse R, Chantler C. Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet 1992;339:280-2. https://doi.org/10.1016/0140-6736(92)91341-5
  21. Reich HN, Troyanov S, Scholey JW, Cattran DC. Toronto Glomerulonephritis Registry: Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007;18: 3177-83. https://doi.org/10.1681/ASN.2007050526
  22. Katafuchi R, Ninomiya T, Mizumasa $T^{(R)}$, Ikeda K, Kumagai H, Nagata M, et al. The improvement of renal survival with steroid pulse therapy in IgA nephropathy. Nephrol Dial Transplant 2008; 23:3915-20. https://doi.org/10.1093/ndt/gfn394